Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.
F. A. Holmes, Joyce O’Shaughnessy(Baylor University Medical Center), Allison Florance, T Anderson, JM Mahoney, Kristi McIntyre(Texas Health Dallas), Rosa I. Gallagher(George Mason University), Virginia Espina(George Mason University), Michael A. Danso, Yasir M. Nagarwala, L. A. Liotta, CK Osborne(Baylor College of Medicine)
Cited by 48
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
|Clinical Cancer Research|2013|744